2025 revealed how data center outages, from fires and mechanical failures to hyperscale cloud region events, can cascade ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

In an increasingly automated and energy-efficient world, single-phase solid-state relays (SSRs) stand out as essential components in modern heating and lighting systems. These extraordinary devices ...

ATLANTA — Eli Lilly’s investigational oral GLP-1 drug orforglipron produced significant weight loss, A1c reduction, and cardiovascular risk factor improvements in the company’s Phase 3 ATTAIN-2 trial ...

Two Sarepta Therapeutics drugs for treating different genetic subsets of patients with Duchenne muscular dystrophy failed the confirmatory study required of their accelerated FDA approvals. Sarepta ...

The biggest stories of the day delivered to your inbox.

Perell has built multiple multi-million-dollar businesses from the ground up and is known for teaching founders how to turn setbacks into strategy. When I asked her how she built lasting success, she ...

Edesa Biotech has shared data from its truncated phase 3 respiratory failure trial, linking the anti-TLR4 antibody to improvements in survival and recovery. The trial enrolled about 100 people who ...

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, ...

Sanofi has dropped its respiratory syncytial virus (RSV) vaccine for toddlers after the candidate underperformed in a phase 3 study. The French Big Pharma was evaluating the intranasal live attenuated ...

NEW YORK – A gene therapy for heart failure being advanced by Bayer's AskBio subsidiary has shown a promising safety profile and early signs of efficacy in a small first-in-human Phase I trial, ...